0000899243-18-002932.txt : 20180205
0000899243-18-002932.hdr.sgml : 20180205
20180205190009
ACCESSION NUMBER: 0000899243-18-002932
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180201
FILED AS OF DATE: 20180205
DATE AS OF CHANGE: 20180205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rubin Karuna
CENTRAL INDEX KEY: 0001730419
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34655
FILM NUMBER: 18575748
MAIL ADDRESS:
STREET 1: C/O AVEO PHARMACEUTICALS, INC.
STREET 2: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVEO PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001325879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617- 531-2130
MAIL ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2018-02-01
0
0001325879
AVEO PHARMACEUTICALS INC
AVEO
0001730419
Rubin Karuna
C/O AVEO PHARMACEUTICALS, INC.
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
Senior VP and General Counsel
Stock Option (right to buy)
1.59
2025-07-06
Common Stock
35000
D
Stock Option (right to buy)
1.08
2026-01-06
Common Stock
30000
D
Stock Option (right to buy)
0.92
2026-05-25
Common Stock
100000
D
Stock Option (right to buy)
0.60
2027-02-07
Common Stock
100000
D
Stock Option (right to buy)
0.60
2027-02-07
Common Stock
33333
D
This option vested as to 25% of the shares underlying such option on July 7, 2016 and the remaining 75% vests in equal monthly installments through July 7, 2019.
This option vests in equal monthly installments beginning February 7, 2016 through January 7, 2020.
This option vests in equal monthly installments beginning June 26, 2016 through May 26, 2020.
This option vests in equal monthly installments beginning March 8, 2017 through February 8, 2021.
On February 8, 2017, the reporting person was granted an option to purchase 50,000 shares of common stock. Subject to the achievement of three performance milestones relating to the company's clinical trials and regulatory filings, one third of the option vests on February 8, 2018, and two thirds of the option vests on February 8, 2019. On June 21, 2017, the first two performance milestones were met. As a result, one third of the option will vest on February 8, 2018, and one third of the option will vest on February 8, 2019, in each case subject to the reporting person's continued service to the company.
/s/ Karuna Rubin
2018-02-05